Korean J Med.  2009 Aug;77(2):152-156.

Current status of drug-resistant tuberculosis and its treatment

Affiliations
  • 1Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute, Seoul National University College of Medicine, Seoul, Korea.

Abstract

Drug-resistant tuberculosis (TB), especially multidrug-resistant (MDR)-TB and extensively drug resistant (XDR)-TB, poses a serious threat to global health because it requires treatment for a long duration and frequent hospitalization, and results in a considerable number of mortalities. In South Korea, MDR is observed in 2.7% of newly diagnosed TB cases and in 14% of re-treatment cases. In addition, 5~20% of MDR-TB could be categorized as XDR-TB. Treatment regimen for MDR or XDR-TB should include 4~5 drugs susceptible to isolated tuberculous bacilli and should be maintained at least 18 months after culture conversion. Pertinent combination of anti-TB drugs and solid compliance are the basis of successful treatment for MDR and XDR-TB patients.

Keyword

Tuberculosis; Drug resistance; Treatment

MeSH Terms

Compliance
Drug Resistance
Extensively Drug-Resistant Tuberculosis
Hospitalization
Humans
Republic of Korea
Tuberculosis
Tuberculosis, Multidrug-Resistant
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr